A Phase I study targeting the APE1/ref-1 redox signaling protein with APX3330: First clinical agent targeting APE1/ref-1 in Cancer.

APX3330 - Apexian, Opus Genetics

http://www.ncbi.nlm.nih.gov/pubmed/41423797

Amber L Mosley; Bert O'Neil; Eyram Kpenu; Hao Liu; Jun Wan; Mark R Kelley; Mateusz Opyrchal; Nehal J Lakhani; Randall Wireman; Richard A Messmann; Sa? Shahda; Sheng Liu

Dec 22, 2025